March 19-20, 2010
University of Washington
Day One, Friday, March 19, 2010
7:30-8:30 Check-In & Registration
8:30 Welcoming Remarks
8:40-10:00 Presentation/Q&A Session
"IP Issues for Pioneers and Generics in
Drugs, Devices, and Biologics"
Samuel E. Webb Partner Stoel Rives LLP, Seattle
10:00-10:30 Networking Break (refreshments will be provided)
10:30-12:00Presentation/Q&A Session
"Immunologic Identity and Biosimilars: How Close is Close
Enough?"
Kirsten L. Vadheim, Ph.D., RAC BioCompliance Consulting,
Inc.
12:00-1:30 Lunch (on your own or host a group)
1:30-3:00 Presentation/Q&A Session
"Regulatory Considerations for Biosimilars: Attitudes of the
FDA"
Andrew Fox Director of Regulatory Affairs Amgen, Inc. Thousand
Oaks, CA
3:00-3:15 Networking & Break (refreshments will be provided)
3:15-4:45 Presentation/Q&A Session
"What is happening where biosimilars are currently available?
–The case of Latin America"
Rafael Alfonso, MD, MSc Research Associate, School of Pharmacy
Pharmaceutical Outcomes Research & Policy Program
University of Washington
Day Two, Saturday, March 20, 2010
7:30-8:30Check-in & registration
8:30-10:00 Presentation/Q&A
"Economic Considerations for Biosimilars: Theory and
Examples"
Kyle Ross, PhD UW-Lilly Senior Post-Doctoral Research Fellow
Pharmaceutical Outcomes Research and Policy Program University
of Washington.
10:00-10:30 Networking Break (refreshments will be provided)
10:30-12:00 Presentation/Q&A Session
"Biosimilars and Clinical Trials: What are the Issues?"
Royce Morrison, MD, CPI Director of Clinical Strategy Charles
River
12:00-1:30 Lunch & Poster Presentations (Lunch provided at UW Tower)
1:30-3:00 Presentation/Q&A Session
"Biochemical and Biophysical Characterization of
Proteins"
Carlos Enrique Catalano, Pharm.D., Ph.D. Professor, Department
of Medicinal Chemistry School of Pharmacy University of
Washington
3:00-3:30 Conference Summary and Take-away Points
Thomas A Baillie, Dean, School of Pharmacy
4:00 Conference Concludes